Technical Analysis for GLAXF - GlaxoSmithKline Plc

Grade Last Price % Change Price Change
A 19.47 1.94% 0.3700
GLAXF closed up 1.94 percent on Friday, January 15, 2021, on 1 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Up Up
Historical GLAXF trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Gapped Up Strength 1.94%
Crossed Above 20 DMA Bullish 4.15%
Crossed Above 50 DMA Bullish 4.15%
180 Bullish Setup Bullish Swing Setup 4.15%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.15%
Inside Day Range Contraction 4.15%
Fell Below 20 DMA Bearish 6.39%
Fell Below 50 DMA Bearish 6.39%
Older End-of-Day Signals for GLAXF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GlaxoSmithKline Plc Description

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Health Pharmaceutical Industry Pharmaceutical Industry In China Pharmaceutical Products Pharmacology Healthcare Products Inflammation Breath Infant Vaccines Asthma Paste Dermatology Immunotherapy A Therapeutic Malt Alfa Syrup Hiv Merck Consumer Healthcare Urinary Tract Infection Cleanser Nasal Spray Rare Diseases Sbi Quell Thk Urinary Tract Infections Mouthwash Rare Disease Toothpaste Glaxosmithkline Consumer Healthcare Products Dermal Patch Decongestants Diclofenac Lamisil

Is GLAXF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.2033
52 Week Low 14.96
Average Volume 351,421
200-Day Moving Average 19.4582
50-Day Moving Average 18.5099
20-Day Moving Average 18.5315
10-Day Moving Average 18.8756
Average True Range 0.6173
ADX 23.36
+DI 26.7132
-DI 11.4973
Chandelier Exit (Long, 3 ATRs ) 17.6581
Chandelier Exit (Short, 3 ATRs ) 19.4319
Upper Bollinger Band 19.4891
Lower Bollinger Band 17.5739
Percent B (%b) 0.99
BandWidth 10.3348
MACD Line 0.1879
MACD Signal Line 0.0989
MACD Histogram 0.0891
Fundamentals Value
Market Cap 97.69 Billion
Num Shares 5.02 Billion
EPS 0.50
Price-to-Earnings (P/E) Ratio 39.25
Price-to-Sales 2.00
Price-to-Book 4.77
PEG Ratio 10.88
Dividend 1.00
Dividend Yield 5.14%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.4150
Resistance 3 (R3) 20.3100 19.8900 20.2575
Resistance 2 (R2) 19.8900 19.6493 19.9425 20.2050
Resistance 1 (R1) 19.6800 19.5007 19.7850 19.7850 20.1525
Pivot Point 19.2600 19.2600 19.3125 19.3125 19.2600
Support 1 (S1) 19.0500 19.0193 19.1550 19.1550 18.7875
Support 2 (S2) 18.6300 18.8707 18.6825 18.7350
Support 3 (S3) 18.4200 18.6300 18.6825
Support 4 (S4) 18.5250